Summary of Key Information:

Reporting Period: Quarter and Year ended March 31, 2026

Nature of Filing / Announcement: Outcome of Board Meeting - Financial Results and Corporate Decisions

Audit Opinion:

Unmodified opinion from statutory auditors Price Waterhouse & Co Chartered Accountants LLP

Key Financial Highlights [Rs in millions]:

Standalone Results:

Quarter Ended March 31, 2026:

  • Revenue from Operations: 5,786.1
  • Other Income: 59.5
  • Total Income: 5,845.6
  • Total Expenses: 5,253.4
  • Profit before exceptional items and tax: 592.2
  • Exceptional Items: (10.8) [Related to manufacturing site closure]
  • Profit before tax: 581.4
  • Tax Expense: 132.6
  • Profit after tax: 448.8
  • EPS: 17.95

Year Ended March 31, 2026:

  • Revenue from Operations: 22,755.8 (33% YoY growth from 17,162.9)
  • Other Income: 284.9
  • Total Income: 23,040.7
  • Total Expenses: 20,466.2
  • Profit before exceptional items and tax: 2,574.5
  • Exceptional Items: (52.5) [Related to manufacturing site closure]
  • Profit before tax: 2,522.0
  • Tax Expense: 646.8
  • Profit after tax: 1,875.2 (62% YoY growth from 1,157.4)
  • EPS: 75.01
  • Other Equity: 8,677.9
  • Cash and Cash Equivalents: 4,477.2
  • Paid-up equity share capital: 50.0 (Face value ₹2 per share)

Segment-wise Performance:

The Company has identified 'Healthcare Segment' as its only reportable segment

Therapy Area-wise Performance for FY26:

  • Oncology: 16,100.9
  • Biopharmaceuticals (CVRM, R&I and V&I): 5,243.2
  • Rare Disease: 214.6

Corporate Actions:

  • Recommended final dividend of ₹36 per equity share of face value ₹2 per share for FY 2025-26
  • Dividend aggregates to ₹900 million, subject to shareholder approval

Other Significant Information:

Key Business Milestones FY26:

  • 11 new regulatory approvals for medicines and indications
  • Durvalumab approvals for endometrial cancer, muscle invasive bladder cancer, gastric cancer, and liver cancer
  • Eculizumab launch for atypical Haemolytic Uremic Syndrome and Paroxysmal Nocturnal Hemoglobinuria
  • Osimertinib approvals for NSCLC in combination therapy and monotherapy
  • Trastuzumab deruxtecan approval for HER2-low and HER2-ultralow metastatic breast cancer
  • Benralizumab approval for eosinophilic granulomatosis with polyangiitis
  • Sodium Zirconium Cyclosilicate approval for hyperkalaemia (in partnership with Sun Pharma)

Company Recognitions:

  • Pharma Company of the Year at ET RePharma Awards
  • Medical Excellence Award for Rare Disease at OPPI India
  • Top Employer India 2025
  • Multiple OPPI Medical Excellence Awards 2025
  • SAS Customer Recognition Awards 2025
  • ET HRWorld EX Awards 2025
  • VOH National Healthcare Awards 2025

Statement of Assets and Liabilities as at March 31, 2026:

  • Total Assets: 19,891.0
  • Total Equity: 8,727.9
  • Total Liabilities: 11,163.1
  • Current assets excluding assets classified as held for sale: 17,321.9
  • Assets classified as held for sale: 77.4
  • Trade receivables: 2,136.8
  • Inventories: 10,273.3
  • Trade payables: 7,827.0 (including micro and small enterprises: 20.4)

Statement of Cash Flows for Year Ended March 31, 2026:

  • Net cash used in operating activities: (151.4)
  • Net cash generated from investing activities: 186.9
  • Net cash used in financing activities: (919.7)
  • Net decrease in cash and cash equivalents: (884.2)
  • Dividend paid: (800.0)
  • Cash and cash equivalents at end of year: 4,477.2